|
Volumn 4, Issue 9, 2004, Pages 1552-
|
Association of type of induction with posttransplant lymphoproliferative disorders [2]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BASILIXIMAB;
DACLIZUMAB;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
LYMPHOCYTE ANTIBODY;
CHRONOBIOLOGY;
CYTOMEGALOVIRUS INFECTION;
DATA ANALYSIS;
EARLY ACUTE REJECTION;
FOLLOW UP;
FOLLOW UP TIME;
GRAFT REJECTION;
HEMATOLOGIC MALIGNANCY;
HUMAN;
IMMUNOLOGICAL TOLERANCE;
IMMUNOSUPPRESSIVE TREATMENT;
INDUCTION THERAPY;
LETTER;
LYMPHOMA;
LYMPHOPROLIFERATIVE DISEASE;
ORGAN TRANSPLANTATION;
POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE;
PRIORITY JOURNAL;
RISK;
FOLLOW-UP STUDIES;
GRAFT REJECTION;
HUMANS;
KIDNEY TRANSPLANTATION;
LYMPHOPROLIFERATIVE DISORDERS;
MULTIVARIATE ANALYSIS;
RISK FACTORS;
|
EID: 4344701827
PISSN: 16006135
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1600-6143.2004.00540.x Document Type: Letter |
Times cited : (4)
|
References (6)
|